MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtha.2024.04.011

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2024

Variant mapping using mass spectrometry-based proteotyping as a diagnostic tool in von Willebrand disease.

Kreft Iris C, van Duijl Tirsa T, van Kwawegen Calvin, Atiq Ferdows, Phan Winny, Schuller Margo B P, Boon-Spijker Mariëtte, van der Zwaan Carmen, Meijer Alexander B, Hoogendijk Arie J, Bierings Ruben, Eikenboom Jeroen C J, Leebeek Frank W G, van den Biggelaar Maartje, Willebrand in the Netherlands (WiN) study group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

von Willebrand disease (VWD) is the most common inherited bleeding disorder, characterized by either partial or complete von Willebrand factor (VWF) deficiency or by the occurrence of VWF proteoforms of altered functionality. The gene encoding VWF is highly polymorphic, giving rise to a variety of proteoforms with varying plasma concentrations and clinical significance.

OBJECTIVES

To address this complexity, we translated genomic variation in VWF to corresponding VWF proteoforms circulating in blood.

METHODS

VWF was characterized in VWD patients (n = 64) participating in the Willebrand in the Netherlands study by conventional laboratory testing, DNA sequencing and complementary discovery, and targeted mass spectrometry-based plasma proteomic strategies.

RESULTS

Unbiased plasma profiling combined with immune enrichment of VWF verified VWF and its binding partner factor VIII as key determinants of VWD and revealed a remarkable heterogeneity in VWF amino acid sequence coverage among patients. Subsequent VWF proteotyping enabled identification of both polymorphisms (eg, p.Thr789Ala, p.Gln852Arg, and p.Thr1381Ala), as well as pathogenic variants (n = 16) along with their corresponding canonical sequences. Targeted proteomics using stable isotope-labeled peptides confirmed unbiased proteotyping for 5 selected variants and suggested differential proteoform quantities in plasma. The variant-to-wild-type peptide ratio was determined in 6 type 2B patients heterozygous for p.Arg1306Trp, confirming the relatively low proteoform concentration of the pathogenic variant. The elevated VWF propeptide/VWF ratio indicated increased clearance of specific VWF proteoforms.

CONCLUSION

This study highlights how VWF proteotyping from plasma could be the first step to bridge the gap between genotyping and functional testing in VWD.

Для цитирования: Kreft Iris C, van Duijl Tirsa T, van Kwawegen Calvin, Atiq Ferdows, Phan Winny, Schuller Margo B P, Boon-Spijker Mariëtte, van der Zwaan Carmen, Meijer Alexander B, Hoogendijk Arie J, Bierings Ruben, Eikenboom Jeroen C J, Leebeek Frank W G, van den Biggelaar Maartje, Willebrand in the Netherlands (WiN) study group. Variant mapping using mass spectrometry-based proteotyping as a diagnostic tool in von Willebrand disease.. Journal of thrombosis and haemostasis : JTH. 2024. DOI: 10.1016/j.jtha.2024.04.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.